GPCR Quote, Financials, Valuation and Earnings

Eli Lilly & Co. has a net margin of -- compared to Structure Therapeutics, Inc.'s net margin of 31.72%. Structure Therapeutics, Inc.'s return on equity of -25.55% beat Eli Lilly & Co.'s return on equity of 106.26%.

Structure Therapeutics, Inc. has a consensus price target of $76.36, signalling upside risk potential of 9.11%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,063.89 which suggests that it could grow by 6.65%. Given that Structure Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Structure Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Structure Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Structure Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.6% to investors and pays a quarterly dividend of $1.50 per share. Structure Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Structure Therapeutics, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Structure Therapeutics, Inc.'s net income of -$65.8M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Structure Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 49.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics, Inc. is -- versus 15.31x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Structure Therapeutics, Inc.'s net margin of 21.32%. Structure Therapeutics, Inc.'s return on equity of -25.55% beat Pfizer Inc.'s return on equity of 10.84%.

Structure Therapeutics, Inc. has a consensus price target of $76.36, signalling upside risk potential of 9.11%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 11.56%. Given that Pfizer Inc. has higher upside potential than Structure Therapeutics, Inc., analysts believe Pfizer Inc. is more attractive than Structure Therapeutics, Inc..

Structure Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Structure Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.61% to investors and pays a quarterly dividend of $0.43 per share. Structure Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Structure Therapeutics, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Structure Therapeutics, Inc.'s net income of -$65.8M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Structure Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 15.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics, Inc. is -- versus 2.37x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals, Inc. has a net margin of -- compared to Structure Therapeutics, Inc.'s net margin of -103.13%. Structure Therapeutics, Inc.'s return on equity of -25.55% beat Rhythm Pharmaceuticals, Inc.'s return on equity of -509.34%.

Structure Therapeutics, Inc. has a consensus price target of $76.36, signalling upside risk potential of 9.11%. On the other hand Rhythm Pharmaceuticals, Inc. has an analysts' consensus of $127.00 which suggests that it could grow by 21.42%. Given that Rhythm Pharmaceuticals, Inc. has higher upside potential than Structure Therapeutics, Inc., analysts believe Rhythm Pharmaceuticals, Inc. is more attractive than Structure Therapeutics, Inc..

Structure Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals, Inc. has a beta of 1.963, suggesting its more volatile than the S&P 500 by 96.257%.

Structure Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Structure Therapeutics, Inc. pays -- of its earnings as a dividend. Rhythm Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Structure Therapeutics, Inc. quarterly revenues are --, which are smaller than Rhythm Pharmaceuticals, Inc. quarterly revenues of $51.3M. Structure Therapeutics, Inc.'s net income of -$65.8M is lower than Rhythm Pharmaceuticals, Inc.'s net income of -$52.9M. Notably, Structure Therapeutics, Inc.'s price-to-earnings ratio is -- while Rhythm Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics, Inc. is -- versus 38.19x for Rhythm Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of -- compared to Structure Therapeutics, Inc.'s net margin of --. Structure Therapeutics, Inc.'s return on equity of -25.55% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.

Structure Therapeutics, Inc. has a consensus price target of $76.36, signalling upside risk potential of 9.11%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 142.25%. Given that Viking Therapeutics, Inc. has higher upside potential than Structure Therapeutics, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Structure Therapeutics, Inc..

Structure Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.

Structure Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Structure Therapeutics, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.

Structure Therapeutics, Inc. quarterly revenues are --, which are smaller than Viking Therapeutics, Inc. quarterly revenues of --. Structure Therapeutics, Inc.'s net income of -$65.8M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Structure Therapeutics, Inc.'s price-to-earnings ratio is -- while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics, Inc. is -- versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.